1 Acetylcholine release at the neuromuscular junction relies on rapid, local and transient calcium increase at presynaptic active zones, triggered by the ion in¯ux through voltage-dependent calcium channels (VDCCs) clustered on the presynaptic membrane. Pharmacological investigation of the role of di erent VDCC subtypes (L-, N-, P/Q-and R-type) in spontaneous and evoked acetylcholine (ACh) release was carried out in adult mouse neuromuscular junctions (NMJs) under normal and pathological conditions. 2 o-Agatoxin IVA (500 nM), a speci®c P/Q-type VDCC blocker, abolished end plate potentials (EPPs) in normal NMJs. However, when neurotransmitter release was potentiated by the presence of the K + channel blocker 4-aminopyridine (4-AP), an o-agatoxin IVA-and o-conotoxin MVIICresistant component was detected. This resistant component was only partially sensitive to 1 mM oconotoxin GVIA (N-type VDCC blocker), but insensitive to any other known VDCC blockers. Spontaneous release was dependent only on P/Q-type VDCC in normal NMJs. However, in the presence of 4-AP, it relied on L-type VDCCs too. 3 ACh release from normal NMJs was compared with that of NMJs of mice passively injected with IgGs obtained from patients with Lambert-Eaton myasthenic syndrome (LEMS), a disorder characterized by a compromised neurotransmitter release. Di erently from normal NMJs, in LEMS IgGs-treated NMJs an o-agatoxin IVA-resistant EPP component was detected, which was only partially blocked by calciseptine (1 mM), a speci®c L-type VDCC blocker. 4 Altogether, these data demonstrate that multiple VDCC subtypes are present at the mouse NMJ and that a resistant component can be identi®ed under`pharmacological' and/or`pathological' conditions.